Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > J Liver Cancer > Volume 12(1); 2012 > Article
Case Report A Case of Advanced Hepatocellular Carcinoma which was Supervening with Renal Cell Cancer Cured by Repeated Transarterial Chemoembolization and Sorafenib after Resection
Bun Kim1, Jae Hoon Min1, Seung Up Kim1,6, Jun Yong Park1,6, Kwang Hoon Lee1,5, Do Youn Lee1,5, Jin Sub Choi1,2,6, Young Deuk Choi1,4, Nam Hoon Cho1,3, Young Nyun Park1,3, Sang Hoon Ahn1,6, Kwang Hyub Han1,6, Chae Yoon Chon1,6, Do Young Kim1,6
Journal of Liver Cancer 2012;12(1):51-57
DOI: https://doi.org/
Published online: February 28, 2012
1Departments of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
2Departments of Surgery, Yonsei University College of Medicine, Seoul, Korea
3Departments of Urology, Yonsei University College of Medicine, Seoul, Korea
4Departments of Pathology, Yonsei University College of Medicine, Seoul, Korea
5Departments of Radiology, Yonsei University College of Medicine, Seoul, Korea
6Liver Cancer Special Clinic, Yonsei University College of Medicine, Seoul, Korea
Corresponding author:  Do Young Kim,
Email: DYK1025@yuhs.ac
  • 485 Views
  • 2 Download
  • 0 Crossref
  • 0 Scopus

Advanced hepatocellular carcinoma (HCC) is difficult to treat and the survival is poor. Here, we present a patient diagnosed as advanced HCC (stage IIIa) which was supervening with early renal cell cancer (stage I). The patient was treated with pre-operational transarterial chemoembolization (TACE) and surgical resection (right hepatectomy, right nephrectomy, and cholecystectomy). Sorafenib were taken continually after surgery. Multiple recurred HCC nodules in remnant liver were detected 2 months later after surgery. Combined treatment modalities including 4 sessions of TACE, and 12 cycles of 5-flurouracil (FU)/carboplatin based hepatic arterial infusional chemotherapy (HAIC) induced complete response. After the diagnosis of advanced HCC, the patient survived 36 months and experienced disease-free status for 19 months.


JLC : Journal of Liver Cancer